Welcome to our dedicated page for Equillium news (Ticker: EQ), a resource for investors and traders seeking the latest updates and insights on Equillium stock.
Equillium Inc. (EQ) is a clinical-stage biotechnology company pioneering therapies for severe autoimmune and inflammatory disorders. This news hub provides investors and stakeholders with timely updates on EQ's scientific advancements, regulatory milestones, and corporate developments.
Access curated press releases and analysis covering key areas including clinical trial results, regulatory communications, research partnerships, and financial performance updates. Our repository simplifies tracking of EQ's novel therapeutic candidates like itolizumab (anti-CD6) and cytokine inhibitors in development.
Bookmark this page for streamlined monitoring of Equillium's progress in addressing conditions such as graft-versus-host disease and lupus nephritis through immunomodulatory approaches. Return regularly for verified updates directly from company filings and authorized sources.
Equillium (Nasdaq: EQ) announced that on October 31, 2025 its Compensation Committee granted inducement nonstatutory stock options to a new employee to purchase 7,200 shares under the company’s 2024 Inducement Plan.
The option exercise price is $1.41 per share, equal to Equillium’s closing price on October 31, 2025. The award vests over four years: 25% on the one-year anniversary of the vesting commencement date and the remainder vesting monthly over the subsequent 36 months, subject to continued service. The grant was approved as an inducement under Nasdaq Listing Rule 5635(c)(4) and is governed by the Inducement Plan and a stock option agreement.
Equillium (Nasdaq: EQ) will host a virtual key opinion leader (KOL) event on November 5, 2025 at 12:00 PM ET to discuss ulcerative colitis (UC) unmet needs and Aryl Hydrocarbon Receptor (AhR) modulation. Experts Francisco J. Quintana, PhD, and Brian Feagan, MD, will review the evolving treatment landscape and the potential of AhR targeting to resolve inflammation and promote mucosal healing.
Company management will present a scientific overview of EQ504, an oral colon‑targeted AhR modulator, summarize preclinical data (IL‑10/IL‑22 signaling, regulatory T‑cell effects, epithelial barrier protection) and outline a Phase 1 proof‑of‑mechanism study expected to initiate mid‑2026. A live Q&A will follow and a replay will be posted in the Investors section of Equillium’s website.
Equillium (Nasdaq: EQ) announced leadership and corporate governance updates effective October 1, 2025, and a contract termination dated September 30, 2025. Stephen Connelly, Ph.D. was promoted to President while retaining his Chief Scientific Officer role. Daniel M. Bradbury moved from Executive Chairman to Chairman of the Board, and Bruce Steel remains CEO and a board member. Both Stephen Connelly and Bala Manian tendered resignations from the board, stated as not resulting from any disagreement with the company. Separately, Equillium and Biocon agreed to terminate their collaboration and license arrangements related to itolizumab.
Company commentary emphasized a sharpened pipeline focus on advancing EQ504 into the clinic and improving capital efficiency.
Equillium (Nasdaq: EQ) announced the granting of inducement awards to two new employees on August 29, 2025. The awards consist of nonstatutory stock options to purchase a total of 150,000 shares of common stock under the company's 2024 Inducement Plan.
The stock options have an exercise price of $1.74 per share, matching Equillium's closing price on the grant date. The options will vest over four years, with 25% vesting after one year and the remaining vesting monthly over 36 months, contingent on continued employment.
Equillium (Nasdaq: EQ), a biotechnology company focused on developing treatments for severe autoimmune and inflammatory disorders, has announced its participation in the upcoming Cantor Global Healthcare Conference 2025. The company's management will engage in a fireside chat on September 5, 2025 at 7:55am ET.
The presentation will be accessible through a live webcast on the company's website under the Investor Relations section, with the replay remaining available for 90 days following the event. Management will also be available for one-on-one meetings with registered conference attendees.
Equillium (Nasdaq: EQ) has secured a significant financing agreement worth up to $50 million from leading healthcare investors to advance EQ504, their novel aryl hydrocarbon receptor (AhR) modulator. The financing includes $30 million upfront for approximately 52.6 million shares at $0.57 per share, with potential for an additional $20 million tied to clinical milestones.
The funding will support EQ504's development as an oral, colon-targeted treatment for ulcerative colitis and pouchitis. A Phase 1 clinical study is planned for mid-2026, with data expected approximately 6 months later. The company expects the initial proceeds to extend its cash runway through 2027.
The financing is led by ADAR1 Capital Management and Janus Henderson Investors, with participation from Adage Capital Partners LP, Coastlands Capital, and Woodline Partners LP.
Equillium (Nasdaq: EQ), a biotechnology company focused on autoimmune and inflammatory disorders, announced a significant shift in its treasury strategy to include cryptocurrency investments. Under CEO Bruce Steel's leadership, the company aims to leverage digital currencies for diversification, liquidity, and potential capital appreciation.
The company reported $11.5 million in cash and equivalents as of June 30, 2025, projecting runway into Q4 2025. While implementing this new financial strategy, Equillium continues its biotech mission, particularly advancing EQ504, its novel aryl hydrocarbon receptor modulator, towards clinical development.
Equillium (Nasdaq: EQ) presented three posters highlighting EQ504, their novel AhR agonist drug candidate, at IMMUNOLOGY2025. The presentations demonstrated EQ504's potential in treating ulcerative colitis through multiple mechanisms. The research showed that EQ504:
1) Promotes immune tolerance by enhancing Treg stability while suppressing inflammatory Th17 responses 2) Demonstrates superior potency compared to its parent compound ITE in inducing CYP1A1 activity and anti-inflammatory cytokines 3) Effectively reduces gut pathology in mouse models of ulcerative colitis 4) Preserves barrier function and promotes healing of intestinal epithelial cells through IL22RA and IL10 expression
According to CSO Dr. Stephen Connelly, these findings highlight EQ504's potential as a treatment for ulcerative colitis, where poor mucosal healing currently limits patient remission.
Equillium (Nasdaq: EQ) received feedback from the FDA regarding itolizumab for first-line treatment of acute graft-versus-host disease (aGVHD). The FDA declined to grant Breakthrough Therapy designation and did not support an Accelerated Approval pathway based on the EQUATOR study data.
The FDA emphasized the importance of Day 29 response outcomes but showed openness to evaluating other endpoints, including longer-term outcomes, if supported by independent data. In response, Equillium plans to accelerate the closure of the EQUATOR study.
The company reported cash and cash equivalents of $14.5 million as of March 31, 2025, which is expected to fund operations into the third quarter of 2025.
FAQ
What is the current stock price of Equillium (EQ)?
What is the market cap of Equillium (EQ)?
